Jacob Chacko - 02 Jan 2026 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: ORIC
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 16:40:09 UTC
Prior SEC filing: 17 Dec 2025
Next SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Christian Kuhlen, attorney-in-fact

Key filing fact

Jacob Chacko filed Form 4 for Oric Pharmaceuticals, Inc. (ORIC) on 06 Jan 2026.

Key facts

This page summarizes Jacob Chacko's Form 4 filing for Oric Pharmaceuticals, Inc. (ORIC).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 06 Jan 2026, 16:40.

Change

Previous filing in this sequence was filed on 17 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001608936 Primary reporting owner

Chacko Jacob

Relationship: PRESIDENT AND CEO, Director
Address: C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Christian Kuhlen, attorney-in-fact
Signature date: 06 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ORIC transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +675,000
Change %
Price: $0.000000
Shares after: 675,000
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 675,000
Exercise price: $8.17
Footnotes: F1

ORIC transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +112,500
Change %
Price: $0.000000
Shares after: 112,500
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 112,500
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.

Footnote F3

1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.